“While the FDA’s viewpoint in its mission to minimize potential risks associated with LDT-based diagnosis is commendable and understandable, the proposed FDA rule constitutes a setback that will negatively impact the diagnostic field for infectious diseases, particularly neglected diseases currently on the rise in the US. “ https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0012116